Phase 3 first-line study of zipalertinib in EGFR exon 20 insertion mutation non-small-cell lung cancer patients open to enrollment Initial monotherapy clinical data for CLN-619 presented at. -Today at 07:02 am- MarketScreener
Cullinan Oncology Announces First Patient Dosed In Phase 1 Trial Evaluating Cln-978, A Novel Cd19xcd3 T Cell Engager, In Relapsed/Refractory B-Cell No menafn.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from menafn.com Daily Mail and Mail on Sunday newspapers.
Cullinan Oncology Announces First Patient Dosed in Phase 1 Trial Evaluating CLN-978, a Novel CD19xCD3 T cell Engager, in Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma tmcnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tmcnet.com Daily Mail and Mail on Sunday newspapers.
Cullinan Oncology Stock (NASDAQ:CGEM), Quotes and News Summary benzinga.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from benzinga.com Daily Mail and Mail on Sunday newspapers.